Rocbrutinib plus R-CHOP yielded a 100% ORR and an 86.7% CR rate in 15 patients with untreated non-GCB DLBCL, warranting randomized evaluation.
News|Videos|December 19, 2017
Updates in Splenic and Nodal Marginal Zone Lymphoma
Author(s)Catherine Thieblemont, MD, PhD
This video reviews updates on the treatment and biology of splenic and nodal marginal zone lymphoma.
Advertisement
In this video, Catherine Thieblemont, MD, PhD, of Hopital Saint-Louis in Paris, discusses updates on the treatment and biology of splenic and nodal marginal zone lymphoma.
Thieblemont gave a presentation on this topic during an education session at the 2017 American Society of Hematology (ASH) Annual Meeting and Exposition, held December 9–12 in Atlanta.
Advertisement
Related to this article
Grade 3/4 neurotoxicity in patients prompted a partial clinical hold on the PALISADES-1 and PALISADES-2 trials of KITE-753 in large B-cell lymphoma.
In a phase 2 trial, orelabrutinib plus sintilimab yielded a 60.7% overall response rate in relapsed/refractory primary CNS lymphoma.
Oral vitamin C improved OS in patients with CCUS or lower-risk myeloid malignancies in the EVITA trial despite missing the clonal growth primary end point.
Advertisement
Advertisement
Trending on CancerNetwork
1
KITE-753 Trials in R/R DLBCL Placed on Partial Clinical Hold for ICANS
2
AI-Measured Tumor Volume on PSMA PET-CT Linked With Survival in Prostate Cancer
3
How Could Rocbrutinib Plus R-CHOP Reshape Frontline Non-GCB DLBCL Treatment?
4
Managing FLOT Toxicity With Dose Reductions in Gastroesophageal Cancer
5